FDA Guideline: CGT Risk–Benefit Assessment, Ethics & Informed Consent Requirements
Future directions in ethical frameworks for genome editing and CGT
Future Directions in Ethical Frameworks for Genome Editing and Cell and Gene Therapy The rapid advancement in cell and gene therapy (CGT) has introduced a myriad of ethical considerations, especially concerning risk-benefit assessments, informed consent, and the overall governance of clinical studies. Regulatory professionals engaged in CGT development must navigate these challenges while adhering to established frameworks set forth by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regulatory bodies. This article aims to provide a comprehensive, step-by-step guide to understanding the ethical frameworks surrounding CGT, particularly focusing on the CGT risk-benefit assessment, ethics…
Training investigators and study staff on CGT specific consent challenges
Training Investigators and Study Staff on CGT Specific Consent Challenges In the rapidly evolving landscape of cell and gene therapy (CGT), training investigators and study staff on the specific challenges related to informed consent is critical for ensuring ethical compliance and enhancing patient engagement. This article serves as a comprehensive tutorial for regulatory, CMC, clinical, and QA leaders working within the CGT domain, and it will detail the ethical considerations, regulatory requirements, and best practices in obtaining informed consent, focusing on the unique risks and benefits presented by CGT products. Understanding the Ethical Landscape of CGT Informed Consent Informed consent…
Documentation of risk benefit reasoning in CGT regulatory submissions
Comprehensive Guide on Documentation of Risk Benefit Reasoning in CGT Regulatory Submissions The documentation of risk-benefit reasoning in cell and gene therapy (CGT) regulatory submissions is critical to ensuring patient safety, ethical compliance, and the successful marketing of new therapies. As regulatory scrutiny increases globally, understanding the nuances of this documentation process is essential for regulatory, CMC, clinical, and QA leaders in the biotech and pharmaceutical industries. This tutorial provides a step-by-step guide to effectively documenting risk-benefit reasoning in CGT submissions. Understanding Risk-Benefit Assessment in Cell and Gene Therapy Risk-benefit assessments are integral to the development and approval process of…
Governance for patient engagement and advisory panels in CGT programs
Governance for Patient Engagement and Advisory Panels in CGT Programs In the evolving landscape of cell and gene therapy (CGT), the importance of patient engagement and advisory panels cannot be overstated. This article serves as a comprehensive tutorial on compliance, focusing on the ethics of CGT risk-benefit assessments, informed consent requirements, and the regulatory obligations concerning patient advisory panels in the United States, United Kingdom, and European Union. Regulatory, CMC, clinical, and QA leaders involved in CGT product development will find this guide particularly useful for navigating these complex ethical landscapes. Understanding the Framework of CGT Risk-Benefit Assessment The risk-benefit…
Global perspectives on CGT ethics from FDA, EMA and academic bodies
Global Perspectives on CGT Ethics from FDA, EMA, and Academic Bodies Cell and gene therapy (CGT) products represent a revolutionary approach in medical treatment. However, with these innovations come a unique set of ethical considerations that need to be navigated diligently. This article focuses on the ethical frameworks established by the U.S. FDA, the European Medicines Agency (EMA), and academic institutions regarding CGT, specifically in the realms of risk-benefit assessment, informed consent, and regulatory oversight. Understanding CGT: Ethical Considerations in Product Development Cell and gene therapies present cutting-edge advancements in the treatment of various genetic disorders and diseases. However, the…